Moderna, Inc. (MRNA)
After hours:
| Previous close | 150.00 |
| Open | 147.64 |
| Bid | 145.75 x 800 |
| Ask | 146.10 x 1400 |
| Day's range | 144.99 - 150.75 |
| 52-week range | 115.61 - 464.85 |
| Volume | |
| Avg. volume | 5,184,346 |
| Market cap | 57.154B |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | 4.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
DGAP-News: Moderna, Inc. / Key word(s): MiscellaneousMedicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK 15.08.2022 / 13:30 The issuer is solely responsible for the content of this announcement.MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) AUTHORIZES MODERNA’S OMICRON-CONTAINING BIVALENT BOOSTER IN THE UKStudy results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1
- EQS Group
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
DGAP-News: Moderna, Inc. / Key word(s): MiscellaneousModerna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses 09.08.2022 / 12:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses Contractually remain
- EQS Group
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
DGAP-News: Moderna, Inc. / Key word(s): MiscellaneousEMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union 22.07.2022 / 14:05 The issuer is solely responsible for the content of this announcement.EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European UnionCAMBRIDGE, MA / July 22, 2022 / Moderna, Inc. (
